Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling

Cancer Research

Volumn 69, Issue 19, 2009, Pages 7696-7703

  Zhao, Liangli ^a   Lee, Brian Y ^a   Brown, David A ^b   Molloy, Mark P ^c   Marx, Gavin M ^d   Pavlakis, Nick ^d   Boyer, Michael J ^e   Stockler, Martin R ^e   Kaplan, Warren ^a   Breit, Samuel N ^b   Sutherland, Robert L ^a   Henshall, Susan M ^a   Horvath, Lisa G ^a,e  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b St Vincent's Hospital   (United States)

^c MACQUARIE UNIVERSITY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1B GLYCOPROTEIN1 PRECURSOR; AMINOPEPTIDASE B; ANTERIOR GRADIENT 2 HOMOLOGUE; BIOLOGICAL MARKER; CYSTEINE RICH PROTEIN 61; DOCETAXEL; FETUIN A; GROWTH DIFFERENTIATION FACTOR 15; MASPIN; MITOXANTRONE; PI 88; PROTEIN PRECURSOR; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN PRECURSOR;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; IC 50; MALE; MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT RESPONSE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEINS; PROTEOMICS; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TAXOIDS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 70350225568     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4901     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512 (Pubitemid 39315317)
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520 (Pubitemid 39315318)
4. Chi KN, Siu LL, Hirte H, et al. A phase I of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14:833-839 (Pubitemid 351231167)
5. Tolcher AW, Chi K, Kuhn J, et al. A Phase II, pharmacokinetic and biological correlative study of Oblimersen sodium and Docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:3854-3861 (Pubitemid 40685606)
6. Patterson SG, Wei S, Chen X, et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006;25:6113-6122 (Pubitemid 44562409)
7. Pchejetski D, Doumerc N, Golzio M, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008;7:1836-1845
8. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by Doctaxel and promotes survival of Docetaxel-treated prostate cancer cells. J Biol Chem 2008;283:20635-20644
9. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-kB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kB inhibition by PS-1145 enhances doctaxel antitumor activity. Clin Cancer Res 2006;12:5578-5586 (Pubitemid 44497276)
10. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-2831 (Pubitemid 40490085)
11. Vilenchik M, Raffo AJ, Benimetskaya L, Shames D, Stein CA. Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002;62:2175-2183 (Pubitemid 34408468)
12. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogenous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216 (Pubitemid 39665537)
13. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 2002;59:1198-1211
14. Song X, Bandow J, Sherman J, et al. iTRAQ experimental design for plasma biomarker discovery. J Proteome Res 2008;7:2952-2958
15. Marx G, Pavlakis N, McCowatt S, et al. Phase 1/2 study of PI-88, a novel heparanase, in combination with Docetaxel in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol GU 2008:abstract 182.
16. Selander KS, Brown DA, Sequeiros GB, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007;16:532-537
17. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. Bethesda (MD): National Cancer Institute; 1998. p. 30.
18. Huang C-Y, Beer TM, Higano CS, et al. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007;13:5825-5833
19. Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007;13:1333-1340 (Pubitemid 350073601)
20. Thompson DA, Weigel RJ. hAG2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is co-expressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 1998;251:111-116
21. Zhang J-S, Gong A, Cheville JC, Smith DI, Young CYF. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005;43:249-259 (Pubitemid 40726870)
22. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Ke Y. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007;10:293-300. (Pubitemid 47351409)
23. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008;68:492-497
24. Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 2008;68:7811-7818
25. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005;65:3796-3805 (Pubitemid 40616358)
26. Rasiah KK, Kench JG, Gardiner-Garden M, et al. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 2006;15:711-716
27. Bauskin AR, Brown DA, Junankar S, et al. The propeptide mediates formation of stromal stores of PROMIC-1:role in determing prostate cancer outcome. Cancer Res 2005;65:2330-2336 (Pubitemid 40490143)
28. Chang B-D, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002;99:389-394 (Pubitemid 34060371)
29. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Immediate expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004;10:6418-6431 (Pubitemid 39346536)
30. Shimizu D, Ishikawa T, Ichikawa Y, et al. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Cancer 2005;27:371-376
31. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;66:4983-4986 (Pubitemid 43852864)
32. Liu T, Bauskin AR, Zaunders J, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-5040 (Pubitemid 37022642)
33. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-5978
34. Wakchoure S, Swain TM, Hentunen TA, et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate 2009;69:652-661
35. Lee DH, Yang Y, Lee SJ, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003;63:4648-4655 (Pubitemid 36951043)
36. Kim K-K, Lee JJ, Yang Y, You K-H, Lee J-H. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008;29:704-712
37. Riedel RF, Porrello A, Pontzer E, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008;7:3141-3149
38. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-2650 (Pubitemid 36842108)
39. Brown DA, Stephan C, Ward RL, et al. Measurements of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96. (Pubitemid 43166181)
40. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock IF. Treatment of hormone-refractory prostate cancer with Docetaxel or Mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14:2763-2767